| INTRODUC TI ON
Primary breast lymphoma is a rare subtype of NHL representing an estimated 1% of all NHL and less than 3% of extranodal lymphomas. [1] [2] [3] Its definition was first proposed in 1972 by Wiseman and Liao as a malignant lymphoma involving predominantly the breast with or without ipsilateral locoregional lymph nodes. 4 By this definition, most primary breast lymphoma patients are classified as stage I or II based on the Ann Arbor Staging System, with the exception of bilateral breast lymphoma, which is considered as stage IV by some investigators. 5 The most common histology is DLBCL, although diverse lymphoma subtypes have been reported. [1] [2] [3] As a rare subentity of DLBCL, PB-DLBCL has been shown to display characteristic patterns of relapse distinct from those of nodal DLBCL. 5 Particularly, a high frequency of extranodal relapses in the breast and CNS has been reported in previous studies. [6] [7] [8] [9] [10] However, due to the rarity of this disease, the current published reports on PB-DLBCL comprise predominantly small retrospective series, with only a few large cohort studies reported so far. Thus, it is unsurprising that the patterns of relapse reported for PB-DLBCL are not consistent across all studies. One major area of controversy is the risk of CNS relapse, which ranges widely from 5% to 19% in the published work. [6] [7] [8] [9] [10] As a result, there is currently no consensus among clinicians with respect to the routine use of prophylactic CNS therapy in PB-DLBCL patients.
The incorporation of rituximab into CT has led to a paradigm shift in the treatment of DLBCL, with a number of phase III studies reporting significant survival benefit of R-CHOP vs CHOP as first-line therapy of DLBCL patients. 11, 12 This benefit from rituximab has also challenged the value of consolidative RT in the treatment of limitedstage DLBCL, as results from one randomized controlled trial have shown that consolidative RT could not offer additional benefit for early stage DLBCL patients treated in the rituximab era. 13 However, in the case of PB-DLBCL, only a few studies have evaluated the role of rituximab, and most of them did not show an advantage in PFS or OS. 7, 14, 15 Given this uncertain benefit of rituximab, whether consolidative RT is beneficial for PB-DLBCL patients who have been treated with rituximab-containing regimens remains unclear.
At present, most reports of PB-DLBCL were from Western countries or regions, with a scarcity of data reported for Chinese patients.
In light of the unresolved clinical issues mentioned above and the lack of large PB-DLBCL series reported from China, a multicentric collaborative effort was initiated by the Leukemia and Lymphoma Committee of the Chinese Geriatric Oncology Society, in order to further elucidate the patterns of progression or relapse and the impact of different treatments on the risk of relapse in PB-DLBCL patients. However, neither the addition of rituximab nor prophylactic intrathecal chemotherapy could effectively prevent CNS relapse for PB-DLBCL patients.
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| MATERIAL S AND ME THODS

| RE SULTS
| Patients' characteristics
One-hundred and eight patients who met the eligibility criteria were included. The baseline characteristics are shown in 
| Treatment
The front-line therapy is summarized in Table 2 . All patients received anthracycline-containing CT, with CHOP or CHOP-like regimens being the most common (77%). A minority of patients (Table S1 ) or between patients treated with and without prophylactic IT (Table   S2 ). Mastectomy was carried out in 19% of patients.
| Patterns of progression or relapse
At a median follow-up of 3.2 years (range, 0.1-11.5 years), 35 (32%) patients developed disease progression or relapse, with 18 patients having 2 or more sites of involvement at first relapse. The median time to first progression or relapse was 1.5 years (range, 0.2-8.2 years).
The time to first progression or relapse was more than 3 years in 10 patients and more than 5 years in 6 patients. The estimated 2-, 5-, and 10-year cumulative risks of all progression or relapse were 20.0%, 37.0%, and 61.6%, respectively ( Figure 1A ). Information regarding relapse sites is shown in Table 3 . The most common site of first progression or relapse was the lymph nodes (43%), followed by the breast (41%) and CNS (24%). Extranodal relapse (n = 25) was more common than relapse confined to only nodal sites (n = 10).
There was no significant difference in the cumulative risk of nodal relapse between patients with and without nodal involvement at initial diagnosis (5-year cumulative risk of nodal relapse, 15.3% vs 21.2%, P = .69; Figure S1A ).
Breast progression or relapse was observed in a total of 16 patients, including 2 patients with breast relapses occurring during salvage therapy. The estimated 5-and 10-year cumulative risks of all breast progression or relapse were 20.0% and 26.9%, respectively ( Figure 1A ).
All ipsilateral breast relapses occurred within the first 3 years following diagnosis, whereas contralateral breast relapses tended to occur later with a median time to relapse of 4.6 years (range, 0.4-5.6 years). Six patients developed isolated CNS relapse without concurrent systemic disease, whereas the remaining 5 patients had CNS disease accompanied by relapse or progression in other sites. Bilateral breast involvement at initial diagnosis was associated with a significantly increased risk of early CNS progression (1-year cumulative risk 33.3% vs 1.0%, P = .037; Figure 1B ), whereas neither regional nodal involvement nor tumor size larger than 5 cm was associated with a higher risk of CNS relapse ( Figure S1B,C) . Notably, of the 9 patients with CD5 positivity, only 1 patient developed CNS relapse.
TA B L E 2
When patterns of progression or relapse were analyzed according to the cell-of-origin classification, there was no significant difference in the cumulative risk of overall progression or relapse or site-specific progression or relapse (eg nodal, breast, and CNS relapse) between GCB and non-GCB subtypes, although a trend towards higher risk of nodal relapse was observed for the non-GCB subtype (P = .057; Figure S2 ). When relapse sites were analyzed according to the time to relapse, there is a major difference in the distribution of relapse sites between early relapse and late relapse (Table 3 ). In the patients (n = 25) whose first relapse occurred within 3 years from initial diagnosis, the most common sites of relapse were the lymph nodes and ipsilateral breast. In the patients (n = 10) whose first relapse occurred more than 3 years from diagnosis, the predominant sites of relapse were the contralateral breast and CNS.
| Impact of treatment methods on patterns of progression or relapse
| Rituximab
The addition of rituximab significantly reduced the overall cumulative risk of progression or relapse in patients with PB-DLBCL (P = .029; Figure 2A ). The estimated 5-year cumulative risk of progression or relapse in patients treated with rituximab and without rituximab was 24% and 57%, respectively. In relapse site-specific analyses, rituximab was associated with significantly decreased risk of nodal relapse (5-year cumulative risk, 35.5% vs 10.0%, P = .012; Figure 2B ) but not a significant reduction in the risk of extranodal relapse (P = .117; Figure 2C ). In particular, rituximab did not mitigate the cumulative risk of relapse in the breast (P = .46; Figure 2D ) or in the CNS (P = .72; Figure 2E ).
| Consolidative RT
Consolidative RT was associated with a significant reduction in the overall cumulative risk of relapse (P = .042; Figure 3A ). In 
| Prophylactic IT
Overall, CNS progression or relapse occurred in 3 of 48 patients who received prophylactic IT and 8 of 60 patients without IT prophylaxis, with no significant difference in the rates of relapse between the two groups (6.3% vs 13.3%, P = .374). In the univariate analysis, prophylactic IT was not associated with a significant reduction in the cumulative risk of CNS relapse (P = .975; Figure 3D ).
| Mastectomy
Mastectomy was not associated with a significant reduction in the overall cumulative risk of progression or relapse (P = .48) compared with biopsy or lumpectomy only, nor did mastectomy decrease the risks of relapse in the breast (P = .94) or CNS (P = .21) ( Figure S4 ).
| Survival and prognostic factors
The median PFS for the entire cohort was 6.3 years (95% CI, 4.2- Results of prognostic factor analyses are detailed in Table 4 .
In multivariate analyses, IPI, rituximab, and RT were significantly associated with PFS. International Prognostic Index was the only significant prognostic factor associated with OS. Regional nodal involvement and tumor size larger than 5 cm were not associated with significant changes in PFS or OS.
| D ISCUSS I ON
As the largest case series of PB-DLBCL in the rituximab era to date, our study revealed a continuous pattern of relapse for PB-DLBCL, which is largely attributable to frequent late relapses in the CNS and contralateral breast. In addition, our study revealed for the first time the differential effect of rituximab on nodal and extranodal relapse The correlation between pathological characteristics and patterns of failure in PB-DLBCL has not been extensively studied.
Previous reports have shown the predominance of non-GCB type in PB-DLBCL, yet reported treatment outcomes were similar between the GCB and non-GCB patients. 20, 21 Consistent with these reports, our analysis found no significant difference in patterns of failure between GCB and non-GCB subgroups, suggesting that cellof-origin classification has limited prognostic value for PB-DLBCL.
CD5 positivity was observed in 10% of our cases, similar to the prevalence of CD5 positivity reported in the general DLBCL population (5%-10%). that levels of rituximab in the cerebrospinal fluid are only 0.1% of matched serum levels following an i.v. dose. 24 In published clinical studies, the impact of rituximab on CNS relapse of DLBCL was also controversial. 25, 26 Villa et al 26 suggested that the beneficial effect of rituximab against CNS relapse might be through superior eradication of systemic disease, which secondarily contributes to a reduction of late CNS relapse, rather than a direct CNS prophylactic effect. As none of our patients had systemic disease at initial diagnosis, and the majority of patients (6 of 11) developed isolated CNS relapse with no concurrent systemic disease, the CNS prophylactic effect of rituximab in this setting might be limited. In terms of breast relapse, there is currently no evidence of a "blood-breast barrier" restricting the passage of i.v. rituximab into the breast tissue. However, as breast relapse can be considered as "local relapse" in PB-DLBCL, this observation suggests systemic immunochemotherapy alone might be insufficient to achieve optimal local tumor control. Given these considerations, additional therapies to reduce local breast relapse and CNS relapse should be considered in the management of PB-DLBCL patients who received rituximab-containing regimens.
The benefit of consolidative RT for the treatment of PB-DLBCL has been confirmed by randomized controlled trial in the prerituximab era, 8 yet the role of RT for PB-DLBCL patients receiving rituximab-based regimens remains largely unknown. Our study showed that consolidative RT significantly reduced the risk of breast relapse, even in those who had received rituximab, suggesting the beneficial effect of RT in PB-DLBCL patients treated with rituximabcontaining regimens. This finding is in line with the abovementioned assumption that immunochemotherapy alone is insufficient to achieve optimal local tumor control, and suggests a complementary benefit between rituximab and RT in the management of PB-DLBCL.
However, our finding seems to be at odds with results of a recently published phase III study that reported no significant difference in event-free survival and OS between limited-stage DLBCL patients treated with R-CHOP with and without RT. 13 This discrepancy could be explained by the different patterns of relapse between PB-DLBCL and DLBCL in general. Relapses in this phase III study were predominantly systemic, and the incidence of local relapse (1.5%)
was much lower compared with that of our cohort. Therefore, the high incidence of local breast relapse and the limited effect of rituximab on the reduction of breast recurrence might contribute to the benefit of RT observed in our PB-DLBCL patients. Another interesting observation is that RT to the involved breast seemed to reduce the risk of contralateral relapse, given that only a few cases received prophylactic RT to contralateral breast in our study. This finding suggests that the risk of contralateral breast relapse is to a large extent associated with local tumor control. Studies into the lymphatic system of breast have revealed the existence of lymphatic channels cross-linking bilateral breast, which might allow direct lymphatic drainage from one breast to the other. 27 Therefore, it is reasonable to postulate that by improving local tumor control, consolidative RT could decrease the likelihood of late lymphatic metastasis of residue disease to the contralateral breast. Although these hypotheses should be regarded as only suggestive due to the lack of sound evidence, they are worthy of further exploration.
The risk of CNS relapse in PB-DLBCL remains controversial with the reported rates of CNS relapse ranging from 5% to 19.6% (see Table   S3 ). 1, [6] [7] [8] [9] [10] 14 In our study, we observed a rate of CNS relapse of 10%
with an estimated 10-year cumulative risk of 28.3%, which is comparable to that of primary testicular DLBCL. 28, 29 Notably, in contrast to the general observation that CNS relapse in DLBCL occurred early (median, 6.7-8.1 months), [30] [31] [32] [33] the PB-DLBCL patients in our study showed a persistent risk of CNS relapse occurring up to 8.2 years after initial diagnosis (median, 3.1 years). In addition, our study showed for the first time that synchronous bilateral breast involvement was significantly associated with a higher risk of early CNS progression compared with patients with unilateral breast disease. However, it is noteworthy that, although patients with unilateral breast lymphoma had a low incidence of CNS progression in the first few years, this risk accumulated gradually, reaching up to 28% at 10 years, suggesting that CNS relapse is still a major cause of treatment failure for these patients. Based on these findings, more effective strategies for CNS prophylaxis against PB-DLBCL need to be explored.
The optimum strategy of CNS prophylaxis in PB-DLBCL has not been established. Rituximab seems to be ineffective against CNS relapse, as discussed above. Furthermore, we found no significant difference in the risk of CNS relapse between patients with and Although both rituximab and RT decreased disease relapse and improved PFS in our study, they were not associated with significant changes in OS. This result might be due to the limited duration of follow-up in the present study. Given the favorable prognosis of PB-DLBCL (median OS, 8-14 years) 6, 7 and the pattern of frequent late relapse, it is possible that a 3.2-year follow-up might be insufficient to detect a significant survival difference between different treatment groups. In addition, the majority of patients who had disease progression received multiple lines of salvage therapy, including the use of rituximab and autologous/allogeneic stem cell transplant, which might also impact the survival outcome.
Several limitations need to be noted in this study. First, evaluation of CNS involvement was not carried out in all patients at diagnosis, which could have resulted in understaging and inclusion of some patients with occult CNS disease. However, patients with occult CNS involvement at diagnosis typically develop clinical CNS progression early (usually earlier than 1 year from diagnosis), whereas our cohort was characterized by frequent late CNS relapse, thus the likelihood of initial CNS involvement for the patients who developed CNS relapse in our series is not very high. Second, the relatively limited follow-up duration could mask the long-term survival difference of patients receiving different treatments. Finally, a central pathology review was not undertaken, which might have an undefined impact given the possible interobserver variability among pathologists. However, all pathologists worked at centers with expertise in the management of lymphoma in our study.
In conclusion, our study provides a comprehensive analysis of clinical features, patterns of failure, and the effect of various therapeutic strategies on the pattern of relapse in a large cohort of Chinese PB-DLBCL patients. Based on our results, a combination of immunochemotherapy with consolidative RT and CNS prophylaxis could be the optimum treatment choice for patients with newly diagnosed PB-DLBCL. One major challenge is to explore effective strategies of CNS prophylaxis because neither rituximab nor prophylactic IT decreased the risk of CNS relapse in PB-DLBCL patients.
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